1 as 3.8 million person-years (mean 7.2 years), in which
1722 events were recorded.
2 ients (1.04%); 70.8% of all events and 84.4% of BARC >/=
3B events were recorded > 30 days after PCI.
3 as 5.1 million person-years (mean 8.5 years), in which
4768 events were recorded, and for stroke was 3.8 million person-y
4 Adverse events were recorded at baseline, 3 hours, and 24 hours postt
5 Adverse events were recorded in 131 (57%) of 231 patients in the exen
6 Adverse events were recorded in 82 (54%) patients who received placeb
7 Adverse events were recorded throughout the study.
8 Adverse events were recorded throughout the study.
9 125
adverse events were recorded, of which 117 were treatment emergent an
10 No grade 4
adverse events were recorded and no treatment-related deaths were rep
11 180 grade 3 or 4
adverse events were recorded in 101 (15%) of 671 patients in the beva
12 Grade 3 or 4
adverse events were recorded in 17 (65%) of 26 patients in cohort 1 a
13 All
adverse events were recorded until 21 days after each immunization; s
14 All
adverse events were recorded.
15 e, number and severity of phototoxic reactions, and
adverse events were recorded over the respective 180-day and 270-day
16 y medication), 63 suspected grade 3 or 4 associated
adverse events were recorded among 57 (3%) children; 31 (2%) in the c
17 Survival outcomes and clinical or biochemical
adverse events were recorded.
18 No
adverse events were recorded.
19 No
adverse events were recorded.
20 Nonserious
adverse events were recorded in 934 participants, most of whom (67.5%
21 No significant changes in seizure frequency or
adverse events were recorded.
22 Potential
adverse events were recorded at 1 and 3 days after supplementation.
23 Predefined sedation-related
adverse events were recorded daily.
24 in the 900 mg dose group, whereas treatment-related
adverse events were recorded in 15 (17%) patients, 25 (29%) patients,
25 Fourteen serious
adverse events were recorded and resolved.
26 reactions to vaccination occurred, and five serious
adverse events were recorded during the study, most of which resolved
27 Serious
adverse events were recorded for 128 (30%) patients treated with etir
28 Serious
adverse events were recorded in 117 (48%) of 246 patients.
29 Serious
adverse events were recorded in 2 of 15 patients (anaemia in 1 patien
30 26 serious
adverse events were recorded in 21 (10%) infants across the study per
31 Serious
adverse events were recorded in 238 (60%) of the total population, an
32 Serious
adverse events were recorded in three (3%) patients who received meth
33 rded until 21 days after each immunization; serious
adverse events were recorded throughout the trial.
34 18 serious
adverse events were recorded, three of which were attributed to the d
35 No serious
adverse events were recorded.
36 e nasal filters were well tolerated, and no serious
adverse events were recorded.
37 No vaccination-related serious
adverse events were recorded.
38 No severe
adverse events were recorded.
39 Solicited and unsolicited
adverse events were recorded, and immune responses were measured.
40 Major
bleeding events were recorded after a median of 6.5 years follow-up.
41 During follow-up, 14
cardiac events were recorded.
42 iovascular deaths and 25,451 non-fatal major
cardiovascular events were recorded among 488,760 participants without prior
43 ding 44,989 participants, in whom 2496 major
cardiovascular events were recorded during a mean 3.8 years of follow-up (ra
44 Possible major
cardiovascular events were recorded prospectively and adjudicated by an inde
45 Claustrophobic events were recorded by the staff.
46 t, mode of delivery and feeding, immunizations, and
medical events) were recorded.
47 Multiple events were recorded in 22.7% admissions; 15% of these experi
48 1626 kidney events, 795 eye events, and 7598
nerve events were recorded during the follow-up period (median 5.0
49 ome potentially related to magnesium sulphate treatment,
no events were recorded from the 2 trials providing data.
50 ] age, 26 [6] years) in the study, 1018 adverse
obstetrical events were recorded in 953 pregnant women (4.8%).